Sheriff’s office warns residents to beware of Bitcoin scams – Placer County

Published March 14, 2024

Our property crimes unit has observed a concerning increase in scams revolving around transferring money into bitcoins. In a recent incident, the victim was convinced by a caller that their email had been compromised and their bank account was implicated in the breach. The victim was then directed to what they believed was their bank, where they were persuaded to transfer $15,000 into Bitcoin under the guise of protecting their funds. Subsequently, the victim received a call from someone posing as the FBI, who convinced them to transfer an additional $8,000 for the same reason. It wasn't until after the second transfer that the victim grew suspicious and reached out to the Sheriffs Office.

These scams are regrettably prevalent and often highly successful. If you ever receive emails or calls alleging an urgent situation that requires transferring money, STOP immediately and contact law enforcement. Neither law enforcement nor legitimate banking institutions will ever ask you to transfer your funds into Bitcoin or gift cards. This should serve as a major red flag indicating something is amiss.

Please assist us in spreading awareness about these types of scams to ensure that your loved ones do not fall prey to them. Together, we can combat these fraudulent activities and safeguard our community's financial well-being.

Continued here:

Sheriff's office warns residents to beware of Bitcoin scams - Placer County

What’s Behind the Bitcoin Price Surge? Vibes, Mostly – WIRED

The latest surge in the price of bitcoin is increasing the clamor around it, says Dal Bianco, drawing in yet more speculators and creating a self-reinforcing cycle. Likewise, when collective confidence in the prospect of further price growth falters, she says, the resultant downturn can be equally sudden. Under these conditions, demand can vanish as rapidly as it forms.

On March 3, Michael Green, chief strategist at asset management firm Simplify, entered into a wager with Peter McCormack, host of the podcast What Bitcoin Did. They were betting on the price of bitcoin. Green wagered $20,000 that bitcoin would not reach a price of $100,000 per coin by the end of the year. McCormack wagered $100,000 that it would.

The bet, Green says, was in part motivated by a desire to highlight areas of weakness in the economic theory presented as dogma by bitcoin evangelists. He takes issue with the way bitcoin is being sold to the investing public as a store of value designed ultimately to be the currency of the future, he says. I think that is a bunch of economic nonsense. Because the supply of bitcoin will shrink steadily over time as people lose access to irrecoverable wallets, Green argues, it cannot support a system of credit, because the cost of borrowing will eventually rise to a point that almost no one can afford.

In January, US regulators approved the first batch of bitcoin exchange-traded funds, which give people a way to invest in the cryptocurrency through a brokerage, as they would a regular stock. The arrival of bitcoin ETFs is said to have catalyzed the latest surge in price, by unlocking a wave of pent-up demand among investorsboth institutions and regular peoplepreviously unable or unwilling to deal with a crypto exchange or risk storing crypto manually themselves. In approving the new bitcoin funds, says Green, regulators have incentivized financial institutions for whom the ETFs represent a new source of revenue to spend tons of money on marketing to drive demand, and in turn disincentivized any emphasis on deficiencies in the logic of bitcoinomics.

The belief in the future potential of bitcoin has become religious, says Green. That missionary zeal is more likely to influence the price, says Green, than any economic mechanism built into the system. Even if McCormack were to lose the wager, he says, it could be chalked up as a fruitful marketing expense. McCormack told WIRED the wager with Green was not a marketing stunt. I did the bet to prove him wrong, he says.

The influence of evangelism on the price of bitcoin limits the opportunity for good-faith debate about the prospects of the Bitcoin system, says Angel.Once you drink the Kool-Aid, you have a powerful financial incentive to preach to the world that bitcoin is the most wonderful thing, he says. If there were a Nobel prize in marketing, it should be given to Satoshi Nakamoto.

Bitcoins biggest boosters embrace that dynamic as well. Bitcoin price appreciation is an advertisement, says Mow. Investors buy in on the prospect of richesand then fall down the rabbit hole themselves, creating a new generation of believers to spread the Bitcoin gospel.

View original post here:

What's Behind the Bitcoin Price Surge? Vibes, Mostly - WIRED

Bitcoin Whales Pull Out Over 21400 BTC From Exchanges In A Week – CoinGape

Bitcoin (BTC) whales have been on the move, withdrawing a substantial amount of BTC from exchanges over the past week. Amid the Bitcoin price surge past $73,000, BTC whales sought to realize their profits and withdrew over 21,000 BTC this week.

Ali Martinez, a crypto analyst, recently took to X and revealed significant Bitcoin whale activity. He noted that a staggering 21,401 BTC has been pulled out of crypto exchanges during this week to cash out the BTC price rally profits.

The impact of this whale activity became particularly pronounced on Thursday, March 14, when a staggering $752 million worth of Bitcoin was withdrawn from crypto exchanges. This marked the highest single-day withdrawal since May 2023, according to data from Into The Block.

Moreover, the consequences of this mass withdrawal were swiftly felt as the Bitcoin price experienced a notable crash on Friday, March 15. BTC crashed over 7% and the bearish trend was spilled all over the crypto market. In addition, the hot PPI report on Thursday expedited the fall.

Furthermore, according to Coinglass data, only $1.81 million worth of BTC is available on exchanges currently. This underscores the importance of Bitcoin supply shock. However, on a positive note, the network has witnessed the emergence of 13 new whales with holdings of over 1,000 BTC. On the other hand, the Bitcoin price decline continued today.

Also Read:How Low Bitcoin Price May Plunge Amid Market Correction?

The Bitcoin price fell lower than the $65,000 level, indicating a plunge of over 13% from its all-time of $73,836 attained this week. As of writing, the Bitcoin price crashed 6.28% to $64,909.21 on Sunday, Match 17. Whilst, the BTC market cap stood at $1.27 billion.

In addition, the 24-hour trade volume for Bitcoin plummeted 15.78% to $51.16 billion. However, despite the recent downturn, BTCs 1-month gains stand at over 25%. The latest bearish turn was also catalyzed by the massive long liquidations.

Coinglass data reveals that $145.34 million Bitcoin liquidations were recorded in the past 24 hours. Out of this, $125.81 million liquidations were long positions, which could have influenced the recent Bitcoin price crash. Whilst, short traders didnt initiate significant liquidations and profited from the bearish trend.

Also Read:Bitcoin (BTC) Price Slumps To $65K, Liquidations Tops $426M

CoinGape comprises an experienced team of native content writers and editors working round the clock to cover news globally and present news as a fact rather than an opinion. CoinGape writers and reporters contributed to this article.

The presented content may include the personal opinion of the author and is subject to market condition. Do your market research before investing in cryptocurrencies. The author or the publication does not hold any responsibility for your personal financial loss.

Link:

Bitcoin Whales Pull Out Over 21400 BTC From Exchanges In A Week - CoinGape

Crypto Prices Today March 18: Bitcoin At $68K, Ethereum At 3600, PEPE Rebounds As WIF Rallies 30% – CoinGape

The top crypto prices today registered a rebound as the Bitcoin (BTC) price extended beyond the $68,000 level again after attaining an all-time high at $73,836. In addition, the Ethereum price sustained the $3,600 mark. Meanwhile, other top altcoins, such as XRP, Cardano (ADA), and Solana (SOL) gained significantly.

The Bitcoin rebounded significantly today. The Bitcoin price was up by 3.23%, reaching $68,462.46 at the time of writing on Monday, March 18. On the other hand, its trading volume slumped 9.80% to $44.32 billion in the last 24 hours. Meanwhile, the crypto boasted a market cap of $1.34 trillion.

In the altcoin arena, the Ethereum price gained by 1.70% to $3,621.67 at press time with a market valuation of $434.85 billion. Whilst, ETH saw its trading volume decline by 3.54%, reaching $19.92 billion. The Solana price continued gaining and soared beyond the $200 level and flipped BNB. The Solana price surged by 10.11%, settling at $202.02. On the contrary, SOL witnessed a 11.99% dip in trade volume to $10.70 billion in the last 24 hours.

Meanwhile, the Binance Coin (BNB) price defied the gaining momentum and was down by 2.38%, reaching $565.73. Moreover, its 24-hour trade volume dipped by 3.03% to $3.64 billion. Whilst, the XRP price continued trading above the $0.62 mark. The XRP price recorded a gain of 1.57%, reaching $0.6219. In contrast, XRPs trading volume plunged 19.97% to $1.79 billion.

Meanwhile, the Cardano price gained 1.12% to $0.6751 today. Whilst, ADA recorded a 22.26% slump in its 24-hour trading volume, settling at $774.07 million. As the top crypto prices recovered from the bearish downturn, popular meme coins extended losses. The Dogecoin price was up by 5.09% to $0.1524 while its rival, Shiba Inu price rose by 10.85% and traded at $0.00002872.

Also Read:Bitcoin Whales Pull Out Over 21,400 BTC From Exchanges In A Week

The Pepe Coin (PEPE) crypto, a popular meme coin, rebounded significantly today. At press time, the Pepe Coin price was up by 2.94% to $0.000007823 with a market valuation of $3.27 billion. In contrast, its 24-hour trade volume plummeted 24.12% to $1.27 billion.

Dogwifhat (WIF), a meme crypto based on the Solana blockchain, recorded a phenomenal surge of over 30% and ranked the top crypto gainer today. The WIF price soared by 30.34% to $3.03 at the time of reporting. Moreover, its trade volume surged by 85.45% to $1.28 billion. Furthermore, the Dogwifhat crypto recorded a high of $3.10 amid the rally recently.

Also Read:Top 3 Takeaways for Crypto Markets from This Weeks Economic Data

CoinGape comprises an experienced team of native content writers and editors working round the clock to cover news globally and present news as a fact rather than an opinion. CoinGape writers and reporters contributed to this article.

The presented content may include the personal opinion of the author and is subject to market condition. Do your market research before investing in cryptocurrencies. The author or the publication does not hold any responsibility for your personal financial loss.

Read more from the original source:

Crypto Prices Today March 18: Bitcoin At $68K, Ethereum At 3600, PEPE Rebounds As WIF Rallies 30% - CoinGape

Bitcoin Halving 2024 What You Need To Know Forbes Advisor UK – Forbes

Table of Contents

Show more Show less

Forbes Advisor has provided this content for educational reasons only and not to help you decide whether or not to invest in cryptocurrency. Should you decide to invest in cryptocurrency or in any other investment, you should always obtain appropriate financial advice and only invest what you can afford to lose.

The next Bitcoin halving will occur in approximately 32 days, according to CoinMarketCap estimates.*

The available supply of conventional currencies rises and falls under the watchful eyes of national central banks, but the total supply ofBitcoinis fixed and immutable.

There will only ever be 21 million Bitcoin. Presently a bit more than 19 million have been mined, leaving just under 2 million left to be created. The Bitcoin protocol automatically reduces the number of new coins issued with each new block in a process called halving.

One of the most important features of Bitcoin is its limited supply and issuance mechanism.

The Bitcoin halving is when the reward forBitcoin miningis cut in half. Halving takes place every four years.

The halving policy was written into Bitcoins mining algorithm aimed to counteractinflationby maintaining scarcity. In theory, the reduction in the pace of Bitcoin issuance means that the price will increase if demand remains the same.

Bitcoins production scarcity is what defines its finiteness, and when reward goes down, supply is constrained, says Chris Kline, chief operating officer of Bitcoin IRA.

A decentralised network of validators verify all Bitcoin transactions in a process called mining. They are paid 6.25 BTC when they are the first to use complex math to add a group of transactions to the Bitcoin blockchain as part of itsproof-of-workmechanism.

At the current Bitcoin price, 6.25 BTC is worth over 300,000, a clear incentive for miners to keep adding blocks of Bitcoin transactions running smoothly.

Those blocks of transactions are added roughly every 10 minutes, and the Bitcoin code dictates that the reward for miners is reduced by half after every 210,000 blocks are created. That happens roughly every four years in periods that are often accompanied by heightened Bitcoin price volatility.

The first Bitcoin halving occurred in November 2012. The next halving was in July 2016, and the most recent halving was in May 2020.

The reward, or subsidy, for mining, started out at 50 BTC per block when Bitcoin was released in 2009. The amount drops in half each time a new halving takes place. For instance, after the first halving, the reward forBitcoin miningdropped to 25 BTC per block.

The last halving will occur in 2140. At that point, there will be 21 million BTC in circulation and no more coins will be created. From there, miners will just be paid with transaction fees.

Richard Baker, CEO of miner and blockchain services provider TAAL Distributed Information Technologies, points out that miners may shift transaction processing power away from BTC once the next halving takes place as they seek more transaction fees elsewhere to make up for lost Bitcoin revenue.

Fewer miners would mean a less secure network, experts say.

On the other hand, while the halving reduces the reward for miners, it equally lowers the supply of new coins without reducing the demand, notes Patricia Trompeter, CEO of cryptocurrency miner Sphere 3D Corp.

If the economic theory holds true, which historically for Bitcoin it has, Bitcoin prices should increase dramatically in response to the supply shock, she says. Although, there is still debate on whether the historical price movement around each halving was a direct product of the halving.

Higher prices would be an incentive for miners to keep processing Bitcoin transactions.

The number of new Bitcoins issued as a reward for miners who add a new block of validated transactions to the Bitcoins blockchain has halved every four years since 2009.

The initial reward was 50 BTC, which would be worth more than 1,000,000 today. Presently, the reward is 6.25BTC, equal to roughly 224,693.

Heres how the reward has lessened every four years since Bitcoin began:

The Bitcoin algorithm dictates halving happens based on a certain creation of blocks. At the current rate, the next halving is expected to happen on or around 15 April 2024.

Given that halving dates are based on current transaction rates, halving dates can only be predicted. Any acceleration of the transaction rate will bring forward the halving date.

The somewhat predictable nature of Bitcoin halvings was designed so that its not a major shock to the network, experts say.

But that doesnt mean there wont be a trading frenzy surrounding Bitcoins next halving.

Historically, there is a lot of Bitcoin price volatility leading up to and after a halving event, says Rob Chang, CEO of Gryphon Digital Mining, a privately held Bitcoin miner. However, the price of Bitcoin typically ends up significantly higher a few months after.

While there are many other factors influencing Bitcoins price, it does seem that halving events are generally bullish for the cryptocurrency after initialvolatilityeases.

Baker says investors should be cautious about the next Bitcoin halving. Although scarcity can drive price appreciation, reduced mining activity could cause the price to level off.

The key point for investors to consider, however, isnt the specific dates of halving events but to focus on the growth of the network overall, Weisberger says. As long as the network continues to grow, the likelihood of Bitcoin fulfilling its potential as a global store of value increases.

Each time Bitcoin goes through a halving, the rate of supply effectively halves too. When demand levels for an asset remain constant but supply is reduced, the asset tends to appreciate in value.

Traders may seek to exploit this dynamic by investing in Bitcoin ahead of next Aprils anticipated halving, in hopes it will increase the value of their holdings.

When the first halving happened in 2012, there was a negligible effect on Bitcoins value, but this was in the cryptocurrencys early days, before rampant speculation began.

In the year ahead of the second halving in 2016, however, Bitcoin went from around 170 to just over 500 (up 194%).

In the 12 months leading up to the May 2020 halving, Bitcoin rose from around 4,000 to roughly 8,000, marking a 100% increase in value.

Were now within four months of the next halving. In April 2023 Bitcoin was valued at approximately 23,000. Since then, BTC has risen to around 36,000.

While previous pre-halving periods have seen tremendous growth, early indications show this one may be different. Regardless, past performance is no indication of future results.

Bitcoin hit a record high of 55,896 at around 10.20am on 11 March 2024.

Bitcoin was designed to halve every four years in order to maintain scarcity as a counterbalance to inflation. The idea is that reducing supply against a backdrop of sustained demand would drive BTC prices up, protecting against the way inflation devalues assets.

Once the last of the total 21 million Bitcoins have been mined, miners who successfully add blocks of validated transactions to the blockchain will be rewarded with transaction fees, rather than newly minted BTC. Its predicted the 21 million limit will be effectively reached by 2140.

After the next halving in April 2024, the mining reward will fall from 6.5 BTC to 3.125 BTC.

Cryptocurrency is unregulated in the UK. The UK regulator, the Financial Conduct Authority, has repeatedly warned investors that they risk losing all their money if they buy cryptocurrency, with no possibility of compensation.

Go here to read the rest:

Bitcoin Halving 2024 What You Need To Know Forbes Advisor UK - Forbes

Bitcoin price predictions: How much more could it rise in 2024? – Euronews

Thinking about investing in the popular cryptocurrency? A recent report predicts that Bitcoin will reach a new all-time high in 2024.

Bitcoin (BTC) is expected to reach a new record of $88,000 (82,000) throughout the year, before it settles around $77,000 at the end of 2024, according to a new report.

The cryptocurrency's current price sits at around $43,000.

UK fintech firm Finder carried out a study based onexpert price predictions of 40 crypto industry specialists on how Bitcoin is expected to perform through to 2030.

Bitcoin, it found, is likely to hit an average peak price of $87,875 in 2024, with some experts predicting it will climb as high as $200,000.

On the flip side, the average lowest price Bitcoin could hit by the end of 2024, is seen as $35,734, the report said, with some predicting it will fall as low as $20,000.

More than half of the experts Finder surveyed expected the price to increase after a so-called "BTC halving event" in April 2024.

A halving event refers to a period every few years when the reward for mining Bitcoin transactions is cut in half. As things stand, those validating Bitcoin transactions currently get 6.25 bitcoins, which could go down to 3.125.

Halving events lead to a lower supply, with fewer Bitcoins made available, thereby leading to higher prices.

Just under half of the 40 panellists surveyed (47%) believe that Bitcoin is going to reach a new all-time high six months after the halving event.

Kadan Stadelmann, CTO of blockchain platform Komodo, said in the report that Bitcoin is probably facing a fair bit of pressure, not only because of the expected halving event but also because "major companies and institutional investors [are] showing growing interest [in Bitcoin, which] is likely to drive demand."

Many experts forecast more buyers on the market following the US Securities and Exchange Commission's recent approval of 11 Bitcoin ETFs (exchange-traded funds), making it easier for individual investors to trade Bitcoin-related investment funds in the US stock exchanges.

The price could be propelled further upward once the US Federal Reserve cuts the historically high benchmark rate, as analysts expect more liquidity to consequently flow into Bitcoin.

However,John Hawkins, senior lecturer at the University of Canberra, believes that cryptocurrency is still little more than a speculative bubble.

"If the new spot Bitcoin ETFs are popular, there could be a temporary price increase. But, in the medium to longer-term, I still regard Bitcoin as a speculative bubble," said Hawkins, adding there were high expectations about similar ETFs entering the market in 2021, but the price crashed later.

BTC is expected to potentially climb to $122,688 (114,310) in 2025 and $366,935 (341,878) in 2030.

However, the truncated mean, a statistical measure of central tendency, puts the expected price at around $220,708 (205,636) by 2030.

Overall, the majority (58%) of panellists believe now is the time to buy BTC; 38% advise people to hold while 5% of panellists are in favour of a sale.

Cryptocurrencies are not regulated in the UK and there is no protection offered by the Financial Ombudsman or the Financial Services Compensation Scheme.

Disclaimer: This information does not constitute financial advice, always do your own research on top to ensure it's right for your specific circumstances. Also remember, we are a journalistic website and aim to provide the best guides, tips and advice from experts. If you rely on the information on this page, then you do so entirely at your own risk.

Link:

Bitcoin price predictions: How much more could it rise in 2024? - Euronews

Two reasons behind the Bitcoin slump and what will drive ‘the next move up’ – DLNews

The Bitcoin bull run is not over despite the price of Bitcoin plummeting to below $67,000, analysts say.

An 8% drop triggered more than $800 million in liquidations in the past 24 hours, according to CoinGlass data. And Bitcoin accounted for about $283 million of those liquidations.

But market watchers are optimistic, pointing to the performance of Bitcoin and Ethereum in recent weeks where they quickly regained value after big price drops.

Macro will rule out here, Jonathan de Wet, chief investment officer at digital asset trading firm ZeroCap, told DL News. If the US economy really hits the skids, then I think well get a more protracted downside. On balance, I still think we are bullish.

Stay ahead of the game with our weekly newsletters

The prediction comes after a rally that has largely been driven by the approval of 10 spot Bitcoin exchange-traded funds in January.

Volumes of $65 billion flowed through US spot Bitcoin ETFs in March alone, breaking records set in February, Bloomberg Intelligence analyst Eric Balchunas tweeted on Thursday.

Bitcoin surged to a record high, surpassing $73,000 earlier this week, and is expected to reach $150,000 to $200,000 over the next year, depending on who you ask.

Analysts gave different reasons as to why crypto prices dropped on Thursday.

Join the community to get our latest stories and updates

De Wet suggested macroeconomic factors likely caused the drop in crypto prices.

We saw outlier inflation figures and lower-than-forecast retail sales in the US on Thursday, he said. High inflation, low growth is a tough scenario for central banks amid a stagflation narrative.

Ryan McMillin, chief investment officer at Australian crypto fund manager Merkle Tree Capital, said the price decline was likely due to leveraged long positions being flushed.

A flush in leverage refers to a market event where traders using borrowed money to buy assets, like Bitcoin, are forced to sell to cover their positions amid a significant drop in asset prices.

Such events have become more frequent since the launch of spot Bitcoin ETFs, according to McMillin.

This could be a new market dynamic we have to get used to, but ultimately a positive to reset leverage before the next move up, he said.

Selling pressure can lead to rapid price declines, triggering a cascade of sell orders from other leveraged positions.

As a result, $546 million worth of long positions were liquidated across the crypto market, with Bitcoin accounting for $220 million, CoinGlass data shows.

There are signs that insitutions are also exiting the market. The washout wiped $2 billion from open interest in both futures and perpetual contracts over the last 24 hours, according to Coinalyze data.

A futures contract is a legal agreement to buy or sell a security at a predetermined price at a specified future date, while a perpetual contract is similar but without an expiry.

This is leveraged longs having their stops hunted, McMillin said, referring to a strategy where traders aim to squeeze others out of their positions by driving an assets price up, triggering so-called stop-loss orders. He added that the open interest wipe-out was a fair whack.

Sebastian Sinclair is a markets correspondent for DL News. Have a tip? Contact Seb at sebastian@dlnews.com.

See original here:

Two reasons behind the Bitcoin slump and what will drive 'the next move up' - DLNews

Binance CEO Predicts Bitcoin Rally Past $80000 As Investments In Crypto ETFs Surge – TradingView

ZyCrypto

Binance CEO Richard Teng has shared his bullish stance on Bitcoin, predicting that the cryptocurrency will soar above $80,000, driven by increasing institutional investments in crypto-backed exchange-traded funds (ETFs).

Speaking at an event in Bangkok on Sunday, the former regulator noted that the launch of spot Bitcoin ETFs in the US earlier this year has already started to attract institutional investors and new fund flows, adding, Were just getting started.

Teng further revealed he expects Bitcoin to soar above $80,000 before the end of the year as crypto demand continues to soar and supply reduces. He, however, emphasized that the rally wont be a straight line and the market will experience ups and downs, which is good for the market.

The pundits prediction of Bitcoin is not new. Earlier last month, Teng surveyed his followers on Bitcoins potential value by the end of 2024, offering options of $40,000, $80,000, and $120,000. Interestingly, the survey results favoured a bullish expectation of $120,000.

In a tweet on Sunday, the CEO further hinted at his bullish stance for BTC when asked about the significance of the number 3 to him in the Thai community.

Many good things in crypto have 3 syllables BTC, BNB, ATH, To The Moon Now you know. He wrote.

Notably, Bitcoin has experienced a remarkable price surge, catalyzed by the recent approval of several spot ETFs earlier this year. This surge propelled Bitcoin to achieve an all-time high of $73,750 last week. Moreover, the total daily crypto exchange volume on March 14 nearly reached $100 billion, marking the first instance since 2021.

The launch of Bitcoin ETFs in the US has also led to relentless inflows, with more endowments, and family offices are expected to step up allocations into Bitcoin ETFs in the near term. According to data from crypto BitMEX Research, ETF net inflows this week topped $2.565 billion, propelling the cumulative net inflows to a staggering $12 billion after 47 days of trading. According to experts like Willy Woo, this could be the tip of the iceberg.

Teng, who took over as CEO after co-founder Changpeng Zhao stepped down in November following the companys $4.3 billion settlement with US authorities, has long advocated crypto adoption. In a recent interview, Teng noted that as more regulators spend time, energy, and resources to understand and formulate regulatory frameworks for crypto, it will instil further trust within the community and user base, leading to mass adoption.

Despite plunging since Thursday due to market participants profit-taking behaviour, Bitcoin demonstrated resilience on Sunday as it attempted to break minor resistance around $68,000.

The market is expected to continue fluctuating within its current range until the supply diminishes, potentially paving the way for a bullish breakout. The crypto asset traded at $67,108 at press time, reflecting a 1.10% drop over the past 24 hours.

Read the original:

Binance CEO Predicts Bitcoin Rally Past $80000 As Investments In Crypto ETFs Surge - TradingView

Bitcoin is Gearing Up For Pre-Halving Retracement Crypto Analyst – TradingView

Key points:

According to Rekt Capital, a renowned crypto analyst on X, the current bull cycle will retain the fundamental trend pattern preceding Bitcoin halving despite significant impact from the ETF. The analyst acknowledged the newly launched ETFs have played a role in how the Bitcoin market has developed. However, he believes there will be a pre-halving retracement, like in the previous bull cycles.

In one of his posts, Rekt Capital predicted Bitcoin is a few days away from entering the Danger Zone. According to him, the Danger Zone is where the pre-halving retracement begins. He used historical data to explain that Bitcoin performs pre-halving retracements 14 to 28 days before the halving event.

To further explain his observation, the renowned analyst showed that Bitcoin retraced by 20% in the days leading to the 2020 Bitcoin halving. Similarly, before the 2016 halving event, the flagship crypto pulled back by 40% after an initial rally.

At the time of Rekt Capitals post, the Bitcoin halving event was 31 days away, and the pioneer crypto had retraced by 11%. BTC had dropped from the recently achieved all-time high (ATH) of $73,794 to around $65,000, according to data from TradingView.

The famous analyst accompanied his prediction with a chart analysis suggesting Bitcoin could experience further price drops in a post-halving re-accumulation phase. He also revealed the post-halving accumulation would prepare the topmost cryptocurrency for a post-halving parabolic upside movement.

Bitcoin traded for $65,469 at the time of writing amid a general market downtime. The newly launched ETFs impact on the current bull run is significant, especially in pushing BTC to a new ATH before the halving event. That is a situation the crypto market did not experience until the current bull cycle.

Read the original:

Bitcoin is Gearing Up For Pre-Halving Retracement Crypto Analyst - TradingView

Bitcoin drops 9% from its ATH as the market shows signs of being ‘overheated’ – Cointelegraph

Bitcoin (BTC) is trading at $68,319 on March 15, down 4.5% over the last 24 hours as the crypto market displays overheated conditions, according to a report by on-chain analytics firm IntoTheBlock.

Data from Cointelegraph Markets Pro and TradingView shows that the price of BTC turned down from its latest all-time high of $73,835 on March 14, dropping 9% to a new weekly low of $65,565 on March 15.

The drop in Bitcoins price has also triggered a sell-off across the market, with the global crypto market cap dropping 4.1% on the day to rest at $2.59 trillion, according to data from CoinMarketCap.

The second largest cryptocurrency by market capitalization, Ether (ETH), has also dropped 5% in the last 24 hours to $3,708. Other top-cap tokens were also flashing red, with BNB (BNB), XRP (XRP), Cardanos ADA (ADA) and Dogecoin (DOGE) losing 2.3%, 7.3%, 5.8%, and 8% of their value, respectively, over the same period.

Solanas SOL (SOL) was the only token among the top 10 cryptocurrencies recording gains, rising 8% over the last 24 hours.

Previously, Cointelegraphwarned of a possible correction in the BTC price due to overheated conditions, as summarized by X user TOBTC.

Data from market intelligence firm IntoTheBlock corroborates this information, highlighting growing leverage in the crypto market, which presents warning signs of a correction.

In this weeks On-chain Insights newsletter, IntoTheBlock reveals that the amount that buyers of Bitcoin perpetual swaps pay those going short is at its highest since October 2021.

In the chart below, IntoTheBlock analysts note BTCs funding rates on Binance and Bybit reached levels of 0.06% and 0.09% yesterday, paid every 8 hours.

These fees translate to an annualized cost of 93% and 168% in order to go long Bitcoin, the report added.

More data from Coinglass reveals that Bitcoin futures open interest (OI) on all exchanges reached its all-time high of $35.55 billion on March 15.

While high OI reflects new buying in the market fueled by increasing inflows into the spot Bitcoin exchange-traded funds (ETFs), overly bullish positioning in derivatives posts a warning sign for the market when open interest grows too high, as IntoTheBlock analysts point out.

The high-leverage conditions are extending beyond centralized exchanges, with loans on decentralized finance (DeFi) networks rising sharply.

The chart below shows that the total debt on all DeFi protocols has doubled in 2024. According to additional data from IntoTheBlock, the total debt increased from around $2 billion at the beginning of January to reach $4.15 billion on March 14.

IntoTheBlock also reports an uptick in the aggregate amount of debt issued through Aave v3 on Ethereum, which has increased by a factor of 2.14 year-to-date.

The amount of wrapped Bitcoin (WBTC) supplied to Aave has increased by more than 10,000 BTC (~$700M) so far in 2024, the report added.

This means the rates in DeFi have increased with increasing demand for leverage.

As such, the firm warns the DeFi ecosystem is accumulating too much risk, which might lead to a price correction in the near term.

Related: Bitcoin shorts stay absent amid 'very normal' sub-$66K BTC price dip

BTC price breached multiple all-time highs in March in an uptrend largely influenced by the success of the spot Bitcoin ETFs in the United States.

Pointing to overheated conditions, the report by IntoTheBlock notes that the average 90-day return for the top 20 crypto-assets (excluding stablecoins) [...] is 103%.

This means that most traders have realized profits from their crypto investments. According to independent analyst and X user Ali, investors are currently sitting on profits of 70% in their holdings.

In a March 14 post on X, analyst Ali shared the following chart from CryptoQuant showing that traders unrealized profit margins reached 69% when the price hit higher highs above $73,000, which is historically associated with upcoming corrections as traders embark on booking profits.

Ali said:

More data from IntoTheBlock shows that 86% of all Bitcoin holders are in profit at current prices, increasing the chances of a continued sell-off in the short term as profit-booking continues.

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision.

Excerpt from:

Bitcoin drops 9% from its ATH as the market shows signs of being 'overheated' - Cointelegraph

Intel CEO Pat Gelsinger, Open AI’s Anna Makanju, Senators Mark Warner and Todd Young, and other power players … – The Washington Post

Washington Post Live, The Posts award-winning live journalism platform, is unveiling its speakers for The Futurist Summit: The New Age of Tech, its second recent major convening focused on technology.

An all-star lineup of Post journalists will moderate interviews with influential business leaders and policy-makers about the promise and risks posed by emerging technologies. The event will be held on Thursday, March 21 at The Post Live Center in The Washington Posts D.C. headquarters.

Notable interviews include:

The summit will also feature an interactive session about the challenge of deepfakes led by Post technology columnist Geoffrey Fowler and a drone demonstration during an interview with Skydio CEO Adam Bry by associate editor Jonathan Capehart.

Todays ever-changing technology presents unlimited opportunities to better co-pilot our lives, said Vineet Khosla, Chief Technology Officer for The Washington Post. The conversations at The Posts tech summit will highlight some of these solutions and explore the pressing questions facing the world. Khosla, a founding engineer of Siri, joined The Post in 2023 from Uber where he was responsible for its routing engine. He will kick off the summit with opening remarks.

View the program agenda and the full list of speakers here.

The Washington Posts Futurist Summit is hosted with presenting sponsor Mozilla.

Originally posted here:

Intel CEO Pat Gelsinger, Open AI's Anna Makanju, Senators Mark Warner and Todd Young, and other power players ... - The Washington Post

Le Monde and Open AI sign partnership agreement on artificial intelligence – Le Monde

As part of its discussions with major players in the field of artificial intelligence, Le Monde has just signed a multi-year agreement with OpenAI, the company known for its ChatGPT tool. This agreement is historic as it is the first signed between a French media organization and a major player in this nascent industry. It covers both the training of artificial intelligence models developed by the American company and answer engine services such as ChatGPT. It will benefit users of this tool by improving its relevance thanks to recent, authoritative content on a wide range of current topics, while explicitly highlighting our news organization's contribution to OpenAI's services.

This is a long-term agreement, designed as a true partnership. Under the terms of the agreement, our teams will be able to draw on OpenAI technologies to develop projects and functionalities using AI. Within the framework of this partnership, and for the duration of the agreement, the two parties will collaborate on a privileged and recurring basis. A dialogue between the teams of both parties will ensure the monitoring of products and technologies developed by OpenAI.

For the general public, the effects of this agreement will be visible on ChatGPT, which can be described, in simple terms, as an answer engine using established facts or comments expressed by a limited number of references. The engine generates the most plausible and predictive synthetic answer to a given question.

The agreement between Le Monde and OpenAI allows the latter to use Le Monde's corpus, for the duration of the agreement, as one of the major references to establish its answers and make them reliable. It provides for references to Le Monde articles to be highlighted and systematically accompanied by a logo, a hyperlink, and the titles of the articles used as references. Content supplied to us by news agencies and photographs published by Le Monde are expressly excluded.

For Le Monde, this agreement is further recognition of the reliability of the work of our editorial teams, often considered a reference. It is also a first step toward protecting our work and our rights, at a time when we are still at the very beginning of the AI revolution, a wave predicted by many observers to be even more imposing than the digital one. We were among the very first signatories in France of the "neighboring rights" agreements, with Facebook and then Google. Here too, we had to ensure that the rights of press publishers applied to the use of Le Monde content referenced in answers generated by the services developed by OpenAI.

This point is crucial to us. We hope this agreement will set a precedent for our industry. With this first signature, it will be more difficult for other AI platforms to evade or refuse to negotiate. From this point of view, we are convinced that the agreement is beneficial for the entire profession.

Lastly, this partnership enables the Socit Editrice du Monde, Le Monde's holding company, to work with OpenAI to explore advances in this technology, anticipating as far as possible any consequences, negative or favorable. It also has the advantage of consolidating our business model by providing a significant source of additional, multi-year revenue, including a share of neighboring rights. An "appropriate and equitable" portion of these rights, as defined by law, will be paid back to the newsroom.

These discussions with AI players, punctuated by this first signature, are born of our belief that, faced with the scale of the transformations that lie ahead, we need, more than ever, to remain mobile in order to avoid the perils that are taking shape and seize the opportunities for development. The dangers have already been widely identified: the plundering or counterfeiting of our content, the industrial and immediate fabrication of false information that flouts all journalistic rules, the re-routing of our audiences towards platforms likely to provide undocumented answers to every question. Simply put, the end of our uniqueness and the disappearance of an economic model based on revenues from paid distribution.

These risks, which are probably fatal for our industry, do not prevent the existence of historic opportunities: putting the computing power of artificial intelligence at the service of journalism, making it easier to work with data in a shorter timeframe as part of large-scale investigations, translating our written content into foreign languages or producing audio versions to expand our readership and disseminate our information and editorial formats to new audiences.

To take the measure of these challenges, we decided to act in steps. The first was devoted to protecting our content and strengthening our procedures. Last year, we first activated an opt-out clause on our sites, following the example of several other media organizations, prohibiting AI platforms from accessing our data to train their generative intelligence models without our agreement. We also collectively discussed and drew up an appendix to our ethics and deontology charter, devoted specifically to the use of AI within our group. In particular, this text states that generative artificial intelligence cannot be used in our publications to produce editorial content ex-nihilo. Nor can it replace the editorial teams that form the core of our business and our value. Our charter does, however, authorize the use of generative AI as a tool to assist editorial production, under strictly defined conditions.

With this in mind, another phase was opened, dedicated to experimenting with artificial intelligence tools in very specific sectors of our business. Using DeepL, we were able to launch our Le Monde in English website and app, whose articles are initially translated by this AI tool, before being re-read by professional translators and then edited and published by a team of English-speaking journalists. At the same time, we signed an agreement with Microsoft to test the audio version of our articles. This feature, now available on almost all our French-language articles published in our app, opens us up to new audiences, often younger, as well as to new uses, particularly for people on the move. The third step is the one that led us to sign the agreement with OpenAI, which we hope will create a dynamic favorable to independent journalism in the new technological landscape that is taking shape.

At each of these stages, Le Monde has remained true to the spirit that has driven it since the advent of the Internet, and during the major changes in our industry: We have sought to reconcile the desire to discover new territories, while taking care to protect our editorial identity and the high standards of our content. In recent years, this approach has paid off. As the first French media organization to rely on digital subscriptions without ever having recourse to online kiosks, we have for several years been able to claim a significant lead in the hierarchy of national general-interest dailies, thanks to an unprecedented number of over 600,000 subscribers. In the same way, our determination to be a pioneer on numerous social media platforms has given us a highly visible place on all of them, helping to rejuvenate our audience.

The agreement with OpenAI is a continuation of this strategy of reasoned innovation. And we continue to guarantee the total independence of our newsroom: It goes without saying that this new agreement, like the previous ones we have signed, will in no way hinder our journalists' freedom to investigate the artificial intelligence sector in general, and OpenAI in particular. In fact, over the coming months, we will be stepping up our reporting and investigative capabilities in this key area of technological innovation.

This is the very first condition of our editorial independence, and therefore of your trust. As we move forward into the new world of artificial intelligence, we have close to our hearts an ambition that goes back to the very first day of our history, whose 80th anniversary we are celebrating this year: deserving your loyalty.

Le Monde

Louis Dreyfus(Chief Executive Officer of Le Monde) and Jrme Fenoglio(Director of Le Monde)

Translation of an original article published in French on lemonde.fr; the publisher may only be liable for the French version.

Read the original here:

Le Monde and Open AI sign partnership agreement on artificial intelligence - Le Monde

Why is Elon Musk suing Open AI and Sam Altman? In a word: Microsoft. – Morningstar

By Jurica Dujmovic

Potential ramifications extend far beyond the courtroom

In a striking turn of events, Elon Musk, Tesla's (TSLA) CEO, has initiated legal action against OpenAI and its leadership, alleging that the organization he helped found has moved from its original altruistic mission toward a profit-driven approach, particularly after partnering with Microsoft (MSFT).

The lawsuit accentuates Musk's deep-seated concerns that OpenAI has deviated from its foundational manifesto of developing artificial general intelligence (AGI) for the betterment of humanity, choosing instead to prioritize financial gains. But is that really so, or is there something else at hand?

Musk was deeply involved with OpenAI since its inception in 2015, as his concerns about AI's potential risks and the vision to advance AI in a way that benefits humanity aligned with OpenAI's original ethos as a non-profit organization.

In 2018, however, Musk became disillusioned with OpenAI because, in his view, it no longer operated as a nonprofit and was building technology that took sides in political and social debates. The recent OpenAI drama that culminated with a series of significant changes in OpenAI's structure and ethos, as well as a what can only be seen as Microsoft's power grab, seems to have sparked Musk's discontent.

To understand his reasoning, it helps to remember that Microsoft is a company with a long history of litigation. Over the years, Microsoft has faced numerous high-profile legal battles related to its market practices.

Here are some prominent cases to illustrate the issue:

-- In the United States v. Microsoft Corp. case, which began in 1998, the U.S. Department of Justice accused Microsoft of holding a monopolistic position in the PC operating-systems market and taking actions to crush threats to that monopoly. In April 2000, the case resulted in a verdict that Microsoft had engaged in monopolization and attempted monopolization in violation of the Sherman Antitrust Act.

-- In Europe, Microsoft has faced significant fines for abusing its dominant market position. In 2004, the European Commission fined Microsoft 497.2 million euros, the largest sum it had ever imposed on a single company at the time??. In 2008, Microsoft was fined an additional 899 million euros for failing to comply with the 2004 antitrust order.

-- In 2013, the European Commission levied a 561 million euro fine against Microsoft for failing to comply with a 2009 settlement agreement to offer Windows users a choice of internet browsers instead of defaulting to Internet Explorer.

In light of these past litigations, it's much easier to understand why OpenAI's CEO Sam Altman's brief departure from the company and subsequent return late last year - which culminated in a significant shift in the organization's governance and its relationship with Microsoft - was the straw that likely broke Musk's back.

After Altman was reinstated, Microsoft solidified its influence over OpenAI by securing a permanent position on its board. Furthermore, the restructuring of OpenAI's board to include business-oriented members, rather than AI experts or ethicists, signaled a permanent shift in the organization's priorities and marked a pivotal turn toward a profit-driven model underpinned by corporate governance.

The consequences of this power grab are plain to see: Microsoft is already implementing various AI models designed by the company in its various products while none of the code is being released to the public. These models also include a specific political and ideological bias that makes them problematic from an ethical point of view. This too, is an issue that cannot be addressed due to the closed-source nature of AI models generated and shaped under the watchful eye of Microsoft.

Musk's own ventures, like xAI and Neuralink, suggest he's still deeply invested in the AI space, albeit in a way he has more control over, presumably to ensure that the technology develops according to his vision for the future of humanity.

On the other hand, proponents of Microsoft's partnership with OpenAI emphasize strategic and mutually-beneficial aspects. Microsoft's $1 billion investment in OpenAI is viewed as a significant step in advancing artificial-intelligence technology as it allows OpenAI to utilize Microsoft's Azure cloud services to train and run its AI software. Additionally, the collaboration is positioned as a way for Microsoft to stay competitive against other tech giants by integrating AI into its cloud services and developing more sophisticated AI models????.

Proponents say Microsoft's involvement with OpenAI is a strategic business decision aimed at promoting Azure's AI capabilities and securing a leading position in the industry. The partnership is framed as a move to democratize AI technology while ensuring AI safety, which aligns with broader industry goals of responsible and ethical AI development. It is also seen as a way for OpenAI to access necessary resources and expertise to further its research, emphasizing the collaborative nature of the partnership rather than a mere financial transaction??.

Hard truths and consequences

While many point out that Musk winning the case is extremely unlikely, it's still worth looking into potential consequences. Such a verdict could mandate that OpenAI returns to a non-profit status or open-source its technology, significantly impacting its business model, revenue generation and future collaborations. It could also affect Microsoft's investment in OpenAI, particularly if the court determines that the latter has strayed from its founding mission, influencing the tech giant's ability to protect its investment and realize expected returns.

The lawsuit's outcome might influence public and market perceptions of OpenAI and Microsoft, possibly affecting customer trust and market share, with Musk potentially seen as an advocate for ethical AI development. Additionally, the case could drive the direction of AI development, balancing between open-source and proprietary models, and possibly accelerating innovation while raising concerns about controlling and misusing advanced AI technologies.

The scrutiny from this lawsuit might lead to more cautious approaches in contractual relationships within the tech sector, focusing on partnerships and intellectual property. Furthermore, the case could draw regulatory attention, possibly leading to increased oversight or regulation of AI companies, particularly concerning transparency, data privacy and ethical considerations in AI development. While Musk's quest might seem like a longshot to some legal experts, the potential ramifications of this lawsuit extend far beyond the courtroom.

More: Here's what an AI chatbot thinks of Elon Musk's lawsuit against OpenAI and Sam Altman

Also read: Microsoft hasn't been worth this much more than Apple since 2003

-Jurica Dujmovic

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

03-09-24 1003ET

Original post:

Why is Elon Musk suing Open AI and Sam Altman? In a word: Microsoft. - Morningstar

Alumis TYK2 Blocker Clears Phase II in Plaque Psoriasis on Heels of Series C – BioSpace

Pictured: Woman scratching psoriatic lesions on her elbow/iStock, helivideo

Alumis on Saturday posted promising data from the Phase II STRIDE study demonstrating that its investigational TYK2 inhibitor ESK-001 can significantly reduce the severity of lesions in patients with moderate-to severe plaque psoriasis.

The results, presented during a late-breaking session at the annual meeting of the American Academy of Dermatology, showed that all dose levels and schedules of ESK-001 resulted in a significantly higher proportion of patients achieving a 75% improvement on the Psoriasis Area and Severity Score (PASI), which is a widely used tool to evaluate the severity of psoriasis.

At week 12, 64.1% of patients treated with a 40-mg, twice-daily regimen achieved the endpoint, also known as PASI-75. Meanwhile, 56.4% of those assigned to the 20-mg, twice-daily and 40-mg, once-daily schedules met the same outcome. These data were all significantly higher than in the placebo group, in which no participant achieved PASI-75.

Even the lowest dosing regimen of 10-mg, once-daily ESK-001 elicited a significantly higher rate of PASI-75 than placebo.

Alumis CMO Jrn Drappa in a statement said that these data support the potential for a best-in-class profile for ESK-001 in psoriasis, pointing to patients who demonstrated a high degree of clinical improvement at week 12 that continued to increase over time.

The biotech is now preparing to take ESK-001 into Phase III trials, with an eye toward launching the drug as an oral therapy with a better efficacy profile than current treatments on the market, Alumis CEO Martin Babler said in a statement. The company will also advance the candidate in other immune-mediated indications.

ESK-001 is a highly selective allosteric inhibitor of the TYK2 protein. The oral drug candidate works by dampening signaling through the IL-12, IL-13 and interferon- receptors, tempering the bodys immune and inflammatory responses.

In STRIDE, this mechanism of action also helped ESK-001 meet key secondary endpoints. At the highest dosing schedule40-mg twice-daily38.5% of treated participants achieved PASI-90, while 15.4% reached PASI-100, indicating a 100% improvement in PASI scores.

In terms of safety, ESK-001 was overall well-tolerated, inducing no treatment-related serious adverse events. Study dropouts due to side effects were low and the study did not find signs of toxicities associated with JAK inhibition.

STRIDEs open-label extension phase, which followed patients up to 16 weeks, likewise showed that PASI endpoint responses increased even further and that ESK-001 continued to be well-tolerated.

Saturdays readout comes days after Alumis closed its $259 million Series C funding round to help bring ESK-001 into late-stage development. The candidate will help it compete with Bristol Myers Squibb, which owns the TYK2 inhibitor Sotyktu that won the FDAs approval in September 2022 for the treatment of moderate-to-sever plaque psoriasis.

Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

View original post here:

Alumis TYK2 Blocker Clears Phase II in Plaque Psoriasis on Heels of Series C - BioSpace

Communicating With Patients With Psoriasis With Skin of Color – MD Magazine

This is a video synopsis/summary of a panel discussion involving Linda Stein Gold, MD; Mona Shahriari, MD, FAAD; and Seemal Desai, MD.

In this conversation, the participants discuss the complexities of treating patients with skin of color who have psoriasis, emphasizing the need for a holistic approach to care. They explore the cultural sensitivities surrounding skin conditions, acknowledging the stigma and isolation that patients may experience, particularly in cultures valuing fair skin.

The importance of recognizing and addressing cultural concerns during patient encounters is highlighted, with a focus on leaving biases behind and creating a judgment-free environment. The participants stress the significance of building trust and understanding individual patient needs and expectations.

Practical strategies for initiating conversations about cultural implications and treatment preferences are discussed, emphasizing the importance of active listening and collaboration in the decision-making process. Building a strong patient-provider relationship is seen as crucial for improving treatment adherence and overall patient outcomes.

Ultimately, the conversation underscores the importance of patient-centered care and the ongoing effort to break down barriers that may exist within the healthcare system, with the goal of providing personalized and effective treatment for all patients.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.

See more here:

Communicating With Patients With Psoriasis With Skin of Color - MD Magazine

Frontline Forum Part 2: Challenges and Opportunities to Enhance Psoriasis Management – Dermatology Times

Before reading, review part 1 here.

The panel delved into the specific needs of patients with melanin-rich skin and provided valuable insights into optimizing psoriasis care for this patient population. They noted that some patients have expressed distrust in the health care system or experience with clinical trials and may prefer topical treatments oversystemic agents.

When it comes to putting [patients with skin of color] on a systemic agent, a lot of them have distrust in the health care system or experience with clinical trials. They dont always want to go on a systemic [treatment], Shahriari said. Theyd rather go on a topical [treatment], and [with] our older-generation special topical corticosteroids, a big concern was hypopigmentation or other pigmentary alterations. In the scalp, the formulations we had werent ideal for tightlycoiled hairs.

The panel also discussed the potential risk of hypopigmentation and other pigmentary alterations with older topical corticosteroids and the need for newer formulations. We want to simplify the treatment regimen. We want to pay attention to skin of color and the hypopigmentation that can come from topical steroids, Stein Gold explained. We want to do a more holistic treatment for the patients [with] psoriasis where we can treat short term as well as a long term. It doesnt mean we wont use combination therapy with these new topicals, combination with topical steroids or systemic agents, but I think theyre [an] important addition to the treatment arm inthis area.

The panelists highlighted the significance of tailored treatment approaches for patients with melanin-rich skin, with Kircik noting, When you look at the statistics, theres so much discordance between the perception of the disease by the provider vs the patient and it doesnt match. This insight underscores the need for health care providers to understand and address the unique experiences and perceptions of psoriasis in patients with melanin-rich skin.

Stein Gold, Shahriari, and Cameron explored emerging oral treatments for the management of plaque psoriasis, emphasizing the novelty of TYK2 inhibition. They discussed the unique POETYK PSO-LTE (NCT04036435) trial design, stressing the importance of the inclusion of an active control arm. Shahriari explained the significance of trials for deucravacitinib (Sotyktu; Bristol Myers Squibb), stating, We had our POETYK PSO trials, which were the pivotal trials for deucravacitinib. And apremilast, our other oral agent on the market, was theactive comparator.

The POETYK PSO-LTE clinical trial assessed the 3-year results of deucravacitinib treatment in adult patients with moderate to severe plaque psoriasis. The trial included 1519 patients who received at least1 dose of deucravacitinib acrossmultiple phases.1

Shahriari provided an overview of the evolution of treatments for plaque psoriasis, stating, After the 2000s, we decided to become more targeted and specific in our treatments for plaque psoriasis, and thats when the era of the biologics started. The panel shared insights into the pivotal role of biologic agents in the shift toward more targeted and specific treatments forplaque psoriasis.

Han discussed diversity within the IL-17 family of biologic agents, stating, Whats interesting to me is that in the IL-17 family, we have so much diversity now: IL-17A inhibitors and IL-17 receptor blockers, a dual IL-17A and IL-17F. This emphasizes the diversity and ongoing development within the IL-17 family of biologic agents, reflecting the evolving landscape ofbiologic treatments.

The panel also discussed the considerations for choosing between biologic and small-molecule treatments and treatment duration. Han also mentioned, I think it makes sense. One of the things that Leon [Kircik] said, to your point of why not just put them on a biologic, with a small-molecule [treatment], you dont have to worry about the half-life, about how long they keep it on board, about developingantidrug antibodies.

Kircik emphasized the importance of topical treatments in combination with systemic therapies and said, I always say that topical treatment is the foundation of dermatologic treatment. No matter what, we have biologics, we have oral treatments, we still use topical treatment for those patients. And we use combination treatment, right? Regardless of what we are doing...oral, systemic, light treatments, I always add topicals. I use biologics in combination with topicals; systemics-topicals; and lighttreatment- topicals.

Reference

See the article here:

Frontline Forum Part 2: Challenges and Opportunities to Enhance Psoriasis Management - Dermatology Times

Health Conditions Linked to Psoriasis: Heart Disease & More – ADDitude magazine

Not available March 19? Dont worry. Register now and well send you the replay link to watch at your convenience.

Learn about psoriasis and other health conditions, or comorbidities, often linked to it in this webinar hosted by WebMD. Nehal N. Mehta, M.D., will explain how these conditions are related to inflammation, which can affect different parts of your body. Hell discuss how treating your psoriasis, and following specific prevention steps, can help protect you from developing other health issues when you live with psoriasis.

In this WebMD webinar, you will learn about:

Have a question for the expert? There will be an opportunity to post questions for the presenter during the live webinar.

Click here to view the full list of on-demand and upcoming WebMD webinars.

Nehal Mehta, M.D., a renowned expert and researcher on psoriasis and related conditions, is a clinical professor of medicine at George Washington University and adjunct professor at the University of Pennsylvania. He was founding chief of Inflammation and Cardiometabolic Diseases at the National Institutes of Health (NIH) and served as principal Investigator of the largest cohort study examining psoriasis impacts on cardiometabolic diseases from 2012 to 2022. Hes a board member of the American Society of Preventive Cardiology and an elected member of the American Society of Clinical Investigation. Hes the inaugural recipient of the Lasker Clinical Scholar Award. He received lifetime achievement awards for his work in the psoriasis community from two international foundations in 2021 and 2023.

Follow ADDitudes full ADHD Experts Podcast in your podcasts app: Apple Podcasts | Google Podcasts | Spotify | Google Play | Amazon Music | RadioPublic | Pocket Casts | iHeartRADIO | Audacy

See the original post:

Health Conditions Linked to Psoriasis: Heart Disease & More - ADDitude magazine

Sharing Innovations in Psoriasis Biologics and Uplifting Women in Dermatology – Dermatology Times

I'm going to walk the team through the head-to-head clinical trial data, but also the real-world data because the reality is a drug may perform beautifully in a controlled clinical trial setting, but the real world is messy, so that drug may not perform in the same way. I'm going to guide the attendees on which drugs offer the best durability of response over time. Spoiler alert: the IL-23's have really held up not only from an efficacy standpoint, but also from a safety standpoint over time, said Mona Shahriari, MD, FAAD, in an interview with Dermatology Times at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California.

Shahriari, an assistant clinical professor of dermatology at the Yale School of Medicine and the associate director of clinical trials at CCD Research in Connecticut, presented pearls from her AAD session, Comparative Efficacy and Relative Ranking of Psoriasis Biologics Using Real-world and Clinical Trial Data. Shahriari reviewed the efficacy of various biologics and systemics for psoriasis in both clinical trials and real-world examples. Shahriari also reviewed the efficacy of biosimilars and their success.

At AAD, Shahriari also participated in a panel during Bristol Myers Squibbs Women Connection Forum. Shahriari spoke alongside Latanya Benjamin, MD, FAAD, FAAP; Alexandra Golant, MD, FAAD; and Jenny Murase, MD, FAAD, to share their personal and professional journeys, as well as advice for women in dermatology.

If there's something that you want, it's okay to ask. I think a lot of times as women, we assume that certain opportunities are given to us based on our credentials, people look at our CV, people look at everything that we've done. But that's not always the case. Sometimes people don't even know that you're interested in activity. I learned that if there was something I was interested in, if I just asked and said, Hey, I just want to throw my name in the hat for XYZ opportunity that's coming up, they've actually looked at me more carefully, and I've been able to partake in that opportunity, said Shahriari when sharing her advice for women wanting to advance in dermatology.

Transcript

Mona Shahriari, MD, FAAD: Hi, my name is Mona Shahriari. I'm an assistant clinical professor of dermatology at Yale University and the associate director of clinical trials at CCD research.

Dermatology Times: What pearls are you sharing during your session, "Comparative efficacy and relative ranking of psoriasis biologics using real-world and clinical data?"

Shahriari: At this year's American Academy of Dermatology meeting, I'm going to be doing a talk that looks at the comparative effectiveness of different biologics and systemics for plaque psoriasis, not only in clinical trial data, but also in real-world data, because we have a busy toolbox of medications. And sometimes, it's tough to know which drug do I reach for first, and if that fails, which drug do I reach for a second? I'm going to really walk the team through the head-to-head clinical trial data, but also the real-world data, because the reality is a drug may perform beautifully in a controlled clinical trial setting, but the real world is messy, so that drug may not perform in the same way. I'm going to guide the attendees on which drugs offer the best durability of response over time. Spoiler alert the IL-23's have really held up not only from an efficacy standpoint, but from a safety standpoint over time. And interestingly, some of our biosimilars have proven to be just as good as our originator drugs. So,we'll walk through the nitty gritty of those details.

Dermatology Times: What other topics or sessions are you looking forward to at AAD?

Shahriari: Well, I have to say the late breaker session is always my absolute favorite. I make sure not to miss that because being on the cutting edge of clinical trials and dermatology research, I want to make sure I'm offering my patients the most innovative treatment for their skin disease. So that is a session I do not miss because I want to make sure I know what the rest of 2024 is going to look like. But also, the JAK Inhibitors: A New Frontier, that was a new session that hit the space last year, heavily attended, and JAK inhibitors are revolutionizing how we treat so many different diseases within dermatology. I really want to see what else is out there on the horizon, and how we can bring this amazing therapy to our patients.

Dermatology Times: What is the significance of the Bristol Myers Squibb Women's Forum Panel that you participated in?

Shahriari: Well, I really think this is a landmark connection form that they put together, because the reality is as women not only in dermatology, but also as career women out there, there are definitely some disparities that go on, whether it's related to pay, whether it's related to promotion, or really just getting your name out there and exposure. And really, the purpose of this woman's connection forum is to not only help us gain connections with other women leaders within the field, and have those friendships develop and networking opportunities develop, but also to hear about the struggles of other women. Sometimes when you normalize it, and you have somebody who you look up to tell you, "You know what, I went through the same challenges. And this is how I overcame them." It can really help you feel closer to those individuals. But also, you realize everybody's human, everyone's going to face challenges, and what can you do to overcome those challenges and not let them get you down?

Dermatology Times: What advice do you have for other women in dermatology?

Shahriari: I really think the 2 main pieces of advice I have is to find a good mentorship network. And I'm calling it a network and not a mentor because in different stages of your life and different aspects of your career, you're going to need different people. And that mentor might be a female, that mentor might be a male. You want to find different individuals to include in that network of yours so you'll have individuals to go through. But also, one other piece of advice I have is if there's something that you want, it's okay to ask. I think a lot of times as women, we assume that certain opportunities are given to us based on our credentials, people look at our CV, people look at everything that we've done. But that's not always the case. Sometimes people don't even know that you're interested in an activity. And I really learned that if there was something I was interested in, if I just asked and said, "Hey, I just want to throw my name in the hat for XYZ opportunity that's coming up, "they've actually looked at me more carefully, and I've been able to partake in that opportunity. So that was one of the simplest pieces of advice I got once upon a time. And it's really done well for me.

Dermatology Times: What positive changes have you seen in dermatology?

Shahriari: I think one thing I've noticed is historically, as a specialty, we used to prescribe a lot of topical agents for our patients. But we've had an explosion of oral and injectable medications for the treatment of various diseases. And I've been really pleased to find a lot of my colleagues jumping on the bandwagon to offer patients some of these newer therapies because sometimes as dermatologists we do want to see more safety data, we do want to see more efficacy data. But I think the value of these newer generation medications, not only from an efficacy standpoint, but also from a safety standpoint is becoming more evident. So, to see my colleagues jump on the bandwagon and offer these to the patients is really going to make a difference for our patients for years and years to come.

One other piece that I've seen is there's been a lot of emphasis on diversity within clinical trials and really allowing for our patients with skin of color to be at the forefront of many activities that we do within dermatology. Because the reality is that historically a lot of our patients with skin of color, they were not in our clinical trials. And when these individuals went to dermatology offices, they were either not getting appropriate treatment, or they were being undertreated. misdiagnosed. And many of my contemporaries and colleagues just didn't feel comfortable caring for these individuals, but as the population of the United States diversifies, and those people who are a minority today become more of the majority, I love that within dermatology, we are prioritizing the needs of these individuals so that we can take care of all of our patients across all skin tones moving forward.

[Transcript lightly edited for space and clarity.]

Read the rest here:

Sharing Innovations in Psoriasis Biologics and Uplifting Women in Dermatology - Dermatology Times

Frontline Forum Part 1: Challenges and Opportunities to Enhance Psoriasis Management – Dermatology Times

As the understanding of psoriasis continues to evolve, the imperative of personalized care has gained prominence, reshaping the traditional paradigms of treatment. In the recentDermatology Timescustom video series Advancements in Psoriasis Care: Navigating Emerging Therapies and Guidelines, experts in the management of skin conditions discussed the latest developments in plaque psoriasis management. The panel discussion included Linda Stein Gold, MD, of Henry Ford Health in Detroit, Michigan; Mona Shahriari, MD, of Yale University School of Medicine in New Haven, Connecticut; Michael Cameron, MD, of Cameron Dermatology in New York, New York; Leon Kircik, MD, of Derm Research, PLLC, in Louisville, Kentucky; and George Han, MD, of Hofstra University in Hempstead, New York. The conversation shed light on the evolving paradigms, evidence-based approaches, and need for individualized care in managing thiscondition (Table).

Stein Gold emphasized the challenges posed by complex treatment regimens and said, The use of complex regimens with multiple topical agents can lead to lower adherence and less effective treatment. This sentiment underscores the critical need to streamline treatment approaches to enhance patient adherence and optimize treatment outcomes.

The panelists also highlighted the impact of treatment complexity on patient adherence, with Cameron noting, The more complex the regimen is, the lower the adherence, which means were less effectively [managing] the disease. This insight underscores the direct correlation between treatment complexity and patient adherence, emphasizing the need for streamlined andpatient-friendly regimens.

Furthermore, Shahriari said, Its really a matter of simplifying the treatment regimen. This sentiment underscores the need to reevaluate treatment approaches and streamline regimens to enhance patient adherence andtreatment efficacy.

In the realm of psoriasis management, the emergence of steroid phobia and evolving patient preferences has sparked critical discussions among health care professionals. Kircik highlighted the growing trend of steroid phobia among patients, stating, There is now this trend that nobody wants to be on steroids. This observation underscores the shifting attitudes toward steroid-based treatments and the impact on patient-provider discussions regarding treatment options.

The panelists also addressed the concerns surrounding patient preferences for nonsteroidal treatment options, with Stein Gold emphasizing the need to consider alternative therapies, stating, I think of steroids as a short-term solution to a long-term problem. Its really a Band-Aid. This sentiment underscores the evolving perspectives on steroid-based treatments and the need to explore nonsteroidal alternatives to address patient preferences and concerns. Additionally, Cameron provided insights into the prevalence of steroid phobia, saying, I find that [for] most of my patients, whether they [have] mild, moderate, or severe [disease], I dont want them using steroidslong term.

Psoriasis management guidelines serve as a critical resource, providing evidence-based recommendations for the management of psoriasis. Stein Gold addressed the limitations of current treatment guidelines and said, The problem is the guidelines are not for psoriasis. Theyre being done for atopic dermatitis right now. This observation sparked a conversation about the need for updated and comprehensive guidelines that align with the evolving landscape ofpsoriasis management.

The panelists also addressed the implications of treatment guidelines on patient care, with Kircik emphasizing the need for individualized treatment approaches, stating, We are looking for new topicals that are steroid freeor nonsteroidal.

Shahriari expressed the importance of defining disease severity in treatment guidelines and noted, I think we need to talk more about the definitions of mild, moderate, [and] severe psoriasis. This perspective highlights the need for clear and comprehensive definitions of disease severity to guide treatment approaches and optimize patient outcomes.

The panel noted that guidelines are often used against providers by attorneys and insurance companies and can be prescriptive rather than informative. The entire panel agreed that guidelines should be based on a review of the literature and provide a comprehensive overview of available treatments rather thanspecific recommendations.

See more here:

Frontline Forum Part 1: Challenges and Opportunities to Enhance Psoriasis Management - Dermatology Times

Evolution and Innovation in Treating Psoriasis in Pediatric Patients – Dermatology Times

When we talk about evolution in treatment for psoriasis, we have come a long way, April W. Armstrong, MD, MPH, told attendees at the Society for Pediatric Dermatology Pre-AAD Meeting.1

April W. Armstrong, MD, MPH

Armstrong, Chief of the Division of Dermatology at the UCLA Health and the David Geffen School of Medicine, added that through this evolution we are looking for treatments that are effective, convenient and safe. Not too long ago, arsenic was used to treat psoriasis,2 she told attendees. Yes, it killed psoriasis but also killed a lot of other things.

Fortunately, she shared there are now options that are meet the 3 important criteria: safe, effective, and even convenient. For instance, biologics have emerged as a good option for treating psoriasis, especially in adults, Armstrong explained. In general, there are a number of factors she considers when choosing among the biologics, which when grouped include tumor necrosis factor (TNF) inhibitors (ie, etanercept, infliximab, adalimumab, certolizumab), interleukin (IL)-17 inhibitors (ie, ixekizumab, secukinumab, brodalumab, bimekizumab), and IL-23 inhibitors (ie, guselkumab, risankizumab, tildrakizumab, ustekinumab [a IL12/23 inhibitor]).

The IL-17 and IL-23 inhibitors are a good choice for robust psoriasis efficacy. In addition, guselkumab, risankizumab, ustekinumab have been shown to be effective for psoriatic arthritis, while IL-17 inhibitors have been shown to be effective for peripheral and axial psoriatic arthritis. There is evolving evidence for the use of IL-23 inhibitors in psoriatic arthritis of the spine. She cautioned that IL-17 inhibitors should be avoided in patients with a history of inflammatory bowel disease and can be associated with increased risk of oral candidiasis.

Meanwhile, Armstrong noted TNF inhibitors should be avoided in patients with hepatitis B and demyelinating disease. They also are not preferred when there is a history of latent tuberculosis or advanced congestive heart failure. Like the other biologics, TNF inhibitors can be effective for psoriatic arthritis (peripheral and axial) and she added that certolizumab has been great in pregnant patients.

Currently, there arebiologics approved for use in pediatric patients. Ustekinumab which inhibits p40 subunit of IL12/23, has been approved for pediatric plaque psoriasis in patients aged 6 years and older. She pointed to the CADMUS Trial, which found that nearly 70% of patients aged 12 years or older with moderate to severe plaque psoriasis achieved sPGA0/1 (vs 5.4 in the placebo group).3

Secukinumab is approved for pediatric patients aged 6 years and older, she said. She shared results from a study comparing secukinumab versus etanercept in this patient population, noting she especially appreciates head to head comparisons of agents because it speaks to the superiority of one medication over another over a time period. In the study, which was present at the EADV Virtual Congress in 2020, 85% of the patients on secukinumab achieved (and maintained) clear (IGA 0/1) at 52 weeks vs 72% on etanercept.

Approved in pediatric patients 6 years and older for moderate to severe psoriasis, Armstrong said ixekizumab has shown high efficacy when compared with placebo, with 50% of patients achieving PASI 100 by week 12 (vs 2% on placebo).

Bimekizumab, the newest approved biologic for adult patients, has shown fast onset, high efficacy, and robust maintenance of response, Armstrong told attendees. Treatment consists of two 160 mg doses every 4 weeks for the first 16 weeks and then every 8 weeks afterwards. She reminded attendees that labs (ie, tuberculosis, liver enzymes, alkaline phosphatase, and bilirubin) should be checked prior to treatment. Oral candidiasis is the most common adverse event, but she said it is manageable without discontinuation with 100 mg to 200 mg fluconazole for 7 days.

Meanwhile, a phase 2 trial of bimekizumab (NCT04718896) is currently underway to assess safety and efficacy in adolescents with moderate to severe plaque psoriasis.

Another important treatment to consider is the tyrosine kinase 2 (Tyk2) inhibitor deucravacitinib, Armstrong told attendees. Currently, deucravacitinib is approved by the US Food and Drug Administration as an oral medication for the treatment of moderate to severe plaque psoriasis in adults. She shared data demonstrating Psoriasis Area and Severity Index (PASI) 75, PASI 90, and Static Physician's Global Assessment (sPGA) 0/1 response sustained through 3 years for patients on the agent, which she added is really impressive.

The tolerability is really where it shines, Armstrong told attendees. It has rates of diarrhea and nausea similar to placebo, and there are low rates of acne and zoster, she explained, but overall the discontinuation rates was lowest for patients on deucravacitinib when compared with patients on placebo or apremilast.

Before initiating treatment, Armstrong noted patients should be evaluated for tuberculosis and baseline liver and hepatitis serologies should be checked in patients with known or suspected liver disease. However, ongoing monitoring is only needed if the patient has liver disease or unmanaged triglycerides.

Im very excited about the possible extension to our pediatric population in the future, Armstrong said. She detailed a phase 3 trial (NCT04772079) is currently underway for pediatric patients with moderate to severe plaque psoriasis looking at safety and efficacy in that patient population. The study is looking at 2 doses across 2 cohorts based on ages (4 to 12 and 12 to 18 years).

The oral phosphodiesterase 4 (PDE4) inhibitor apremilast is also a new medication that has shown efficacy in pediatric patients, according to Armstrong. It currenly is approved for adults regardless of severity, she said. She shared results of a placebo-controlled study of patients with moderate to severe plaque psoriasis aged 6 to 17 years that found almost one-third were clear or almost clear at week 16 (vs 11% for placebo).

Armstrong briefly noted 2 innovative products in the pipeline. JNJ-77242113 is an oral therapeutic peptide selectively targeting IL-23R, she told attendees.4 DC-806 allosterically blocks the same biochemical step as the anti-IL-17 antibodies.

In the topical category, Armstrong pointed to tapinarof and roflumilast as novel non-steroidal agents. Tapinarof, currently approved for adult patients, is an aryl hydrocarbon receptor (AhR) agonist that reduces TH17 cytokines; increases antioxidant activity via Nrf2 pathway; increases filaggrin, loricrin, and involucrin, and decreases Th2 cytokines. The PSOARING 1 study found that 40% of patients on tapinarof 1% cream daily achieved PASI 75 by week 12. Armstrong added that when tapinarof is stopped, patients are able to maintain clear/almost clear status for about 4 months. My opinion is it is probably similar to or stronger than a class 3 topical steroid, she told attendees. Armstrong is hopeful it will become available for pediatric patients in the near future.

Roflumilast is a PDE4 inhibitor approved for patients aged 6 years and older, Armstrong said. Overall it is quite well tolerated. In my opinion, it is probably similar to a class 3 topical steroid, she said. She uses it in clinical practice, but there are some tricks to make sure your patient has access to it, and knowing which local pharmacies are used to working with it.

References

1. Armstrong A. Updates in Psoriasis Management and New Therapeutics. Presented at: 36th Annual Pre-AAD Meeting of the Society for Pediatric Dermatology; March 7, 2024. San Diego, California.

2. Sarfraz R. H16 Arsenic to biologics: psoriasis treatment through the ages. British Journal of Dermatology. 2023; 188(Supplement 4. ljad113.298

3. Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594-603. doi:10.1016/j.jaad.2015.07.002

4. Bissonnette R, Pinter A, Ferris LK, et al. An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis. N Engl J Med. 2024;390(6):510-521. doi:10.1056/NEJMoa2308713

The rest is here:

Evolution and Innovation in Treating Psoriasis in Pediatric Patients - Dermatology Times